Morgan Stanley Clene Inc. Call Options Transaction History
Morgan Stanley
- $1.27 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CLNN
# of Institutions
40Shares Held
6.22MCall Options Held
287KPut Options Held
162K-
Vanguard Group Inc Valley Forge, PA2.62MShares$14.9 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA922KShares$5.23 Million0.0% of portfolio
-
Scoggin Management LP New York, NY375KShares$2.13 Million0.05% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL273KShares$1.55 Million0.0% of portfolio
-
Csenge Advisory Group270KShares$1.53 Million0.01% of portfolio
About Clene Inc.
- Ticker CLNN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 63,502,000
- Market Cap $360M
- Description
- Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral scleros...